JP2020527174A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527174A5
JP2020527174A5 JP2020523235A JP2020523235A JP2020527174A5 JP 2020527174 A5 JP2020527174 A5 JP 2020527174A5 JP 2020523235 A JP2020523235 A JP 2020523235A JP 2020523235 A JP2020523235 A JP 2020523235A JP 2020527174 A5 JP2020527174 A5 JP 2020527174A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
heterocycloalkyl
haloalkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020523235A
Other languages
English (en)
Japanese (ja)
Other versions
JP7159307B2 (ja
JP2020527174A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/042128 external-priority patent/WO2019014618A1/en
Publication of JP2020527174A publication Critical patent/JP2020527174A/ja
Publication of JP2020527174A5 publication Critical patent/JP2020527174A5/ja
Application granted granted Critical
Publication of JP7159307B2 publication Critical patent/JP7159307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020523235A 2017-07-13 2018-07-13 Atrキナーゼの複素環式阻害剤 Active JP7159307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531951P 2017-07-13 2017-07-13
US62/531,951 2017-07-13
PCT/US2018/042128 WO2019014618A1 (en) 2017-07-13 2018-07-13 HETEROCYCLIC INHIBITORS OF KINASE ATR

Publications (3)

Publication Number Publication Date
JP2020527174A JP2020527174A (ja) 2020-09-03
JP2020527174A5 true JP2020527174A5 (https=) 2021-08-12
JP7159307B2 JP7159307B2 (ja) 2022-10-24

Family

ID=64998660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523235A Active JP7159307B2 (ja) 2017-07-13 2018-07-13 Atrキナーゼの複素環式阻害剤

Country Status (23)

Country Link
US (3) US10392376B2 (https=)
EP (1) EP3651768B1 (https=)
JP (1) JP7159307B2 (https=)
KR (1) KR102676822B1 (https=)
CN (2) CN117466884A (https=)
AU (1) AU2018301696B8 (https=)
CA (1) CA3069693A1 (https=)
DK (1) DK3651768T3 (https=)
ES (1) ES2974334T3 (https=)
FI (1) FI3651768T3 (https=)
HR (1) HRP20240368T1 (https=)
HU (1) HUE066043T2 (https=)
IL (1) IL271930B (https=)
LT (1) LT3651768T (https=)
MX (1) MX2020000386A (https=)
PH (1) PH12020500072A1 (https=)
PL (1) PL3651768T3 (https=)
PT (1) PT3651768T (https=)
RS (1) RS65466B1 (https=)
SI (1) SI3651768T1 (https=)
SM (1) SMT202400106T1 (https=)
WO (1) WO2019014618A1 (https=)
ZA (1) ZA202000148B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
US10377591B2 (en) 2017-07-07 2019-08-13 Zebra Technologies Corporation Input handling for media processing devices
HUE066043T2 (hu) * 2017-07-13 2024-07-28 Univ Texas A TR kináz beterociklusos inhibitorai
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム Atrキナーゼの複素環式阻害剤
CN111655688B (zh) * 2017-09-08 2023-09-29 蓝谷制药有限责任公司 经取代的吡咯并吡啶类化合物作为atr抑制剂
JP7341156B2 (ja) * 2018-03-16 2023-09-08 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム Atrキナーゼの複素環式阻害剤
TW202028209A (zh) * 2018-09-27 2020-08-01 大陸商重慶複創醫藥研究有限公司 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
CN118619944A (zh) * 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN113121524B (zh) * 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
EP4159734B1 (en) 2020-05-29 2025-08-13 Wuxi Life Fountain Biotech Co., Ltd. Fluoropyrrolopyridine compound and application thereof
MX2023000198A (es) * 2020-07-03 2023-02-22 Antengene Discovery Ltd Inhibidores de atr y usos de estos.
WO2022171034A1 (zh) * 2021-02-10 2022-08-18 江苏先声药业有限公司 作为hpk1抑制剂的双环类化合物及其应用
IL308409A (en) * 2021-05-12 2024-01-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Sulfoximine-containing atr inhibitor compound
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
GB0501999D0 (en) * 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2009523161A (ja) 2006-01-11 2009-06-18 アストラゼネカ アクチボラグ モルホリノピリミジン誘導体と療法におけるその使用
MX2009002046A (es) 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
WO2008032072A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
JP2008115166A (ja) * 2006-10-10 2008-05-22 Daiichi Sankyo Co Ltd ピリジルフェニルメチルスルホン誘導体
WO2008125833A1 (en) 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds
US20080292588A1 (en) 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives
EP2178866A2 (en) * 2007-07-09 2010-04-28 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009007751A2 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CA2692945A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Compounds - 945
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
CN102143746A (zh) 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
KR20170015566A (ko) * 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
WO2010120996A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピラジン
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
DK3077397T3 (da) 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン
PL3152212T3 (pl) 2014-06-05 2020-06-15 Vertex Pharmaceuticals Inc. Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
KR102569226B1 (ko) 2014-10-13 2023-08-22 아트린 파마슈티컬스 엘엘씨 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
HUE066043T2 (hu) 2017-07-13 2024-07-28 Univ Texas A TR kináz beterociklusos inhibitorai
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム Atrキナーゼの複素環式阻害剤
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム Atrキナーゼの複素環式阻害剤

Similar Documents

Publication Publication Date Title
JP2020527174A5 (https=)
HRP20240368T1 (hr) Heterociklički inhibitori atr kinaze
JP6903796B2 (ja) Fgfr4阻害剤としての二環式複素環
JP6336665B2 (ja) Fgfr阻害剤としての置換三環式化合物
AU2005278292B2 (en) Novel substituted imidazole derivatives
AU2007323644B2 (en) Compounds modulating c-fms and/or c-kit activity and uses therefor
KR101817221B1 (ko) 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
DK2719699T3 (en) Triazolopyraziner particular, compositions thereof and methods of use thereof
RU2018138471A (ru) Гетероциклические соединения в качестве ингибиторов киназы RET
CA3198809A1 (en) Heterocyclic spiro compounds and methods of use
CA3054161A1 (en) Isoquinolines as inhibitors of hpk1
JP2009538825A5 (https=)
EP3310779A1 (en) Compounds and compositions for inhibiting the activity of shp2
AU2021370660A1 (en) Heterocyclic spiro compounds and methods of use
RU2017138100A (ru) Имидазолонилхинолины и их применение в качестве ингибиторов киназы атм
KR20150068956A (ko) 세린/트레오닌 키나아제 억제제
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
HRP20170349T1 (hr) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
JP2013531684A5 (https=)
KR20130043198A (ko) 키나제 억제제로서 치환된 이미다조퀴놀린 유도체
AU2013225533A1 (en) Amido spirocyclic amide and sulfonamide derivatives
JP6888006B2 (ja) Mnk1およびmnk2を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
CN102399233A (zh) PI3K和mTOR双重抑制剂类化合物
CN105611933A (zh) 抗增生性化合物
JP2014510037A5 (https=)